Yingyi Liu

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

Xiaoshan Wang, Yifeng Bai, Vivek Verma et al. · JNCI Journal of the National Cancer Institute · 2022 · 255 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Tanshinone IIA protects human coronary artery endothelial cells from ferroptosis by activating the NRF2 pathway

Lina He, Yingyi Liu, Kun Wang et al. · Biochemical and Biophysical Research Communications · 2021 · 77 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression

Kequan Xu, Peng Xia, Xiangdong Gongye et al. · Molecular Metabolism · 2022 · 74 citations · Full text

Medicine, Molecular Biology, Oncology +12

Amentoflavone prevents ox-LDL-induced lipid accumulation by suppressing the PPARγ/CD36 signal pathway

Jialing Zhuang, Yingyi Liu, Zhenzhen Li et al. · Toxicology and Applied Pharmacology · 2021 · 50 citations

Life Sciences, Biochemistry, Pharmacology +14

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati et al. · Journal of the American Academy of Dermatology · 2023 · 49 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13